|
Market Closed -
Nasdaq
01:30:00 21/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 514.65 USD | +2.53% |
|
+6.07% | +13.52% |
| 15/10 | Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653 | MT |
| 09/10 | Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children | MT |
Company Valuation: Vertex Pharmaceuticals Incorporated
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55,834 | 74,127 | 1,04,849 | 1,03,707 | 1,15,026 | 1,27,225 | - | - |
| Change | - | 32.76% | 41.44% | -1.09% | 10.91% | 10.61% | - | - |
| Enterprise Value (EV) 1 | 48,309 | 63,349 | 93,630 | 97,591 | 1,08,418 | 1,21,492 | 1,19,681 | 1,18,724 |
| Change | - | 31.13% | 47.8% | 4.23% | 11.09% | 12.06% | -1.49% | -0.8% |
| P/E | 24.4x | 22.5x | 29.3x | -194x | 29.6x | 33.5x | 27x | 22.3x |
| PBR | 5.53x | 5.33x | 5.96x | 6.4x | 6.17x | 8.14x | 6.46x | 5.24x |
| PEG | - | 0.5x | 3.51x | 2x | -0x | -15.61x | 1.1x | 1.1x |
| Capitalization / Revenue | 7.37x | 8.3x | 10.6x | 9.41x | 9.58x | 9.59x | 8.74x | 7.69x |
| EV / Revenue | 6.38x | 7.09x | 9.49x | 8.86x | 9.03x | 9.16x | 8.22x | 7.18x |
| EV / EBITDA | 10.8x | 12.8x | 20.6x | 108x | 19.8x | 27.3x | 19.2x | 16.5x |
| EV / EBIT | 11.1x | 13.2x | 21.4x | 140x | 20.6x | 21.8x | 19.6x | 16.4x |
| EV / FCF | 20.1x | 16.1x | 28.1x | -123x | 33.9x | 67.4x | 25.2x | 23x |
| FCF Yield | 4.99% | 6.2% | 3.56% | -0.81% | 2.95% | 1.48% | 3.96% | 4.35% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 9.01 | 12.82 | 13.89 | -2.08 | 15.32 | 14.99 | 18.62 | 22.56 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 7,574 | 8,931 | 9,869 | 11,020 | 12,001 | 13,269 | 14,565 | 16,542 |
| EBITDA 1 | 4,470 | 4,941 | 4,556 | 902.8 | 5,473 | 4,443 | 6,248 | 7,186 |
| EBIT 1 | 4,344 | 4,793 | 4,375 | 695.6 | 5,263 | 5,583 | 6,114 | 7,228 |
| Net income 1 | 2,342 | 3,322 | 3,620 | -535.6 | 3,953 | 3,891 | 4,892 | 5,868 |
| Net Debt 1 | -7,525 | -10,778 | -11,218 | -6,116 | -6,608 | -5,733 | -7,544 | -8,501 |
| Reference price 2 | 219.60 | 288.78 | 406.89 | 402.70 | 453.36 | 501.95 | 501.95 | 501.95 |
| Nbr of stocks (in thousands) | 2,54,252 | 2,56,691 | 2,57,683 | 2,57,529 | 2,53,719 | 2,53,461 | - | - |
| Announcement Date | 26/01/22 | 07/02/23 | 05/02/24 | 10/02/25 | 12/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.54x | 9.06x | 27.07x | -.--% | 13TCr | |
| 35.75x | 12.79x | 26.94x | 0.55% | 1,10600Cr | |
| 37.14x | 6.26x | 17.62x | 2.1% | 61TCr | |
| 36.08x | 8.31x | 17.14x | 2.43% | 50TCr | |
| 20.6x | 4.98x | 12.38x | 2.63% | 37TCr | |
| 104.7x | 5.86x | 25.15x | 2.37% | 35TCr | |
| 21.05x | 5.51x | 13.55x | 2.9% | 29TCr | |
| 21.56x | 4.37x | 12.5x | 2.02% | 26TCr | |
| 26.98x | 6.96x | 12.46x | 2.37% | 23TCr | |
| -44.72x | 6.87x | 26.59x | 2.15% | 19TCr | |
| Average | 29.27x | 7.10x | 19.14x | 1.95% | 40.27TCr | |
| Weighted average by Cap. | 34.38x | 8.14x | 20.11x | 1.79% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- VRTX Stock
- Valuation Vertex Pharmaceuticals Incorporated
Select your edition
All financial news and data tailored to specific country editions
